筛选条件 共查询到30条结果
排序方式
The IRENA lncRNA converts chemotherapy-polarized tumor-suppressing macrophages to tumor-promoting phenotypes in breast cancer

期刊: NATURE CANCER, 2021; 2 (4)

Although chemotherapy can stimulate antitumor immunity by inducing interferon (IFN) response, the functional role of tumor-associated macrophages in t......

Downregulation of the FTO m(6)A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors

期刊: NATURE CANCER, 2021; 2 (6)

Post-transcriptional modifications of RNA constitute an emerging regulatory layer of gene expression. The demethylase fat mass- and obesity-associated......

Overcoming therapy resistance in EGFR-mutant lung cancer

期刊: NATURE CANCER, 2021; 2 (4)

Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients with non-small cell lung cancer harboring epidermal gro......

Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse

期刊: NATURE CANCER, 2021; 2 (8)

Chemotherapy is a standard treatment for pediatric acute lymphoblastic leukemia (ALL), which sometimes relapses with chemoresistant features. However,......

Transcriptional control of CBX5 by the RNA-binding proteins RBMX and RBMXL1 maintains chromatin state in myeloid leukemia

期刊: NATURE CANCER, 2021; 2 (7)

Kharas and colleagues identify the RNA-binding proteins RBMX and RBMXL1 as AML tumor promoters that alter chromatin compaction and hence cell survival......

Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy

期刊: NATURE CANCER, 2021; 2 (6)

Combining cyclin-dependent kinase (CDK) inhibitors with endocrine therapy improves outcomes for patients with metastatic estrogen receptor-positive br......

Engineering-enhanced CAR T cells for improved cancer therapy

期刊: NATURE CANCER, 2021; 2 (8)

Melenhorst and colleagues review the current status of chimeric antigen receptor T cell therapies, focusing on the rapid progress achieved in this are......

Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders

期刊: NATURE CANCER, ; ()

Cyclin-dependent kinases (CDKs) 4 and 6 inhibitors (CDK4/6is) are effective in metastatic breast cancer, but they have been only modestly effective in......

Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer

期刊: NATURE CANCER, 2021; 2 (1)

Kras-activating mutations display the highest incidence in pancreatic ductal adenocarcinoma. Pancreatic inflammation accelerates mutant Kras-driven tu......

Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma

期刊: NATURE CANCER, 2021; 2 (1)

Malignant solid tumors are characterized by aberrant vascularity that fuels the formation of an immune-hostile microenvironment and induces resistance......

Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia

期刊: NATURE CANCER, 2021; 2 (3)

Yang and colleagues perform a network system-pharmacology approach and clinical data integration, and identify LCK and BCL2 signaling as the molecular......

Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities

期刊: NATURE CANCER, 2021; 2 (2)

Garofano et al. use single-cell RNA-sequencing data to classify glioblastomas along a metabolic axis of mitochondrial and glycolytic/plurimetabolic st......

MTSS1 suppresses mammary tumor-initiating cells by enhancing RBCK1-mediated p65 ubiquitination

期刊: NATURE CANCER, 2020; 1 (2)

Tumor-initiating cells (TICs) are considered the culprits of cancer development and progression. Dysregulation of metastasis suppressor protein 1 (MTS......

Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy

期刊: NATURE CANCER, 2020; 1 (12)

Immune checkpoint blockade (ICB) has improved outcomes for patients with advanced cancer, but the determinants of response remain poorly understood. H......

cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis

期刊: NATURE CANCER, 2022; 3 (11)

Senolytics, drugs that kill senescent cells, have been proposed to improve the response to pro-senescence cancer therapies; however, this remains chal......

共30条页码: 1/2页15条/页